Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

The tumor microenvironment (TME), the complex environment in which tumors develop, has
been increasingly targeted for cancer treatment in recent years. Aggressive pituitary tumors …

Objective A somatic mutational hotspot in the SF3B1 gene was reported in lactotroph
tumours. The aim of our study was to examine the prevalence of driver SF3B1 variants in a …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …

Pituitary tumors (PT) are mostly benign, although occasionally they demonstrate aggressive
behavior, invasion of surrounding tissues, rapid growth, resistance to conventional …

Cushing disease (CD) is caused by a pituitary tumor which oversecretes adrenocorticotropic
hormone (ACTH). It is a serious endocrine disease associated with increased mortality and …

Radiotherapy, conventional or radiosurgery, has been used to control prolactin secretion
and tumour growth in prolactinomas both as part of multimodal therapy or rarely as primary …

Purpose To describe the clinical presentation and treatment outcomes in a nationwide
cohort of patients with giant prolactinomas. Methods Register-based study of patients with …

From a cohort of 171 patients comprising 121 aggressive pituitary tumours (APT) and 50
pituitary carcinomas (PC), the clinicopathological or five-tiered classification based on …